Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus…

StudyJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi· Jul 2026

Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.

Cheng-Fa Yeh, Chi-Chung Chen, Chih-Cheng Lai … Wen-Pin Su

Read paper

Infectious DiseaseStudyQ1IF 3.5

Mitomycin C plus ciprofloxacin fully protected mice against high-burden Vibrio vulnificus infection.

Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.

Cheng-Fa Yeh … Wen-Pin Su

Journal of microbiology, immunology, and infection · Jul 2026 · Q1 in General Medicine

Background

Vibrio vulnificus is a highly virulent pathogen associated with rapidly progressive sepsis and necrotising soft-tissue infection, particularly among patients with diabetes or chronic liver disease.

Methods

We performed an integrated preclinical assessment of mitomycin C (mitomycin C) alone and in combination with ciprofloxacin (ciprofloxacin) using in vitro susceptibility testing and a neutropenic murine model challenged with increasing inocula of V. vulnificus.

1.4 × 10^7 CFU/mL

Results

1.4 × 10^7 CFU/mL

fully protected even against a very high bacterial dose

More results

The combination regimen was not associated with dose-dependent myelosuppression, and no hepatotoxicity or nephrotoxicity was observed.

Exposure to subinhibitory concentrations of mitomycin C did not result in increased minimum inhibitory concentrations over time.

“

Conclusion · 1 of 3

MMC-CIP combination therapy demonstrated synergistic efficacy against severe V. vulnificus infection in a neutropenic mouse model and may represent a promising therapeutic option.

Conclusion · 2 of 3

Dose-limiting myelotoxicity and the potential for resistance necessitate cautious dosing and further clinical investigation. This study addresses a critical therapeutic gap in severe V.

Conclusion · 3 of 3

vulnificus infection by proposing a mechanistically rational, dose-optimized adjunctive strategy supported by robust preclinical evidence.

Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.

Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.

Related papers